Ciaranello Andrea L, Seage George R, Freedberg Kenneth A, Weinstein Milton C, Lockman Shahin, Walensky Rochelle P
Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
AIDS. 2008 Nov 12;22(17):2359-69. doi: 10.1097/QAD.0b013e3283189bd7.
Antiretroviral drugs can prevent mother-to-child transmission of HIV infection, but in-utero antiretroviral exposure may be associated with neurologic symptoms due to mitochondrial toxicity. We sought to identify the currently recommended regimen to prevent mother-to-child transmission that optimally balances risks of pediatric HIV infection and neurologic mitochondrial toxicity.
Published MTCT and mitochondrial toxicity data were used in a decision analytic model of MTCT among women in sub-Saharan Africa.
We investigated the HIV and mitochondrial toxicity risks associated with no antiretroviral prophylaxis and five recommended regimens ranging from single-dose nevirapine to three-drug antiretroviral therapy (ART). Sensitivity analyses varied all parameters, including infant feeding strategy and the disability of mitochondrial toxicity relative to HIV.
Provision of no antiretroviral drugs is the least effective and least toxic strategy, with 18-month HIV risk of 30.4% and mitochondrial toxicity risk of 0.2% (breastfed infants). With increasing drug number and duration, HIV risk decreases markedly (to 4.9% with three-drug ART), but mitochondrial toxicity risk also increases (to 2.2%, also with three-drug ART). Despite increased toxicity, three-drug ART minimizes total adverse pediatric outcomes (HIV plus mitochondrial toxicity), unless the highest published risks are true for both HIV and mitochondrial toxicity, or the disability from mitochondrial toxicity exceeds 6.4 times that of HIV infection.
The risk of pediatric mitochondrial toxicity from effective regimens to prevent mother-to-child transmission is at least an order of magnitude lower than the risk of HIV infection associated with less-effective regimens. Concern regarding mitochondrial toxicity should not currently limit the use of three-drug ART to prevent mother-to-child transmission where it is available.
抗逆转录病毒药物可预防母婴传播HIV感染,但宫内抗逆转录病毒暴露可能因线粒体毒性而与神经症状相关。我们试图确定目前推荐的预防母婴传播方案,该方案能在儿童HIV感染风险和神经线粒体毒性风险之间实现最佳平衡。
已发表的母婴传播和线粒体毒性数据被用于撒哈拉以南非洲地区女性母婴传播的决策分析模型。
我们调查了与不进行抗逆转录病毒预防以及从单剂量奈韦拉平到三联抗逆转录病毒疗法(ART)的五种推荐方案相关的HIV和线粒体毒性风险。敏感性分析对所有参数进行了变化,包括婴儿喂养策略以及线粒体毒性相对于HIV的致残性。
不提供抗逆转录病毒药物是效果最差且毒性最小的策略,18个月时HIV感染风险为30.4%,线粒体毒性风险为0.2%(母乳喂养婴儿)。随着药物数量和疗程增加,HIV感染风险显著降低(三联抗逆转录病毒疗法时降至4.9%),但线粒体毒性风险也增加(三联抗逆转录病毒疗法时也升至2.2%)。尽管毒性增加,但三联抗逆转录病毒疗法能将儿童总体不良结局(HIV感染加线粒体毒性)降至最低,除非已发表的HIV感染和线粒体毒性的最高风险数据属实,或者线粒体毒性导致的致残性超过HIV感染的6.4倍。
有效预防母婴传播方案导致儿童线粒体毒性的风险至少比效果较差方案导致的HIV感染风险低一个数量级。目前,对于线粒体毒性的担忧不应限制在有条件的地区使用三联抗逆转录病毒疗法预防母婴传播。